Phase II Trial of Eprenetapopt (APR-246) in Combination with Azacitidine (AZA) As Maintenance Therapy for TP53 Mutated AML or MDS Following Allogeneic Stem Cell Transplantation (SCT)

Authors
Category Primary study
JournalBLOOD
Year 2021
This article has no abstract
Epistemonikos ID: fb115f93e909c087ea9b37f46b8b4d9725f3b972
First added on: Feb 13, 2025